Reported 3 days ago
Recursion Pharma's stock has surged nearly 28% following the FDA's announcement to phase out certain animal testing requirements, thereby boosting biotech firms utilizing AI alternatives. In contrast, Intel's stock has fallen due to escalating trade tensions exacerbated by new Chinese tariffs on semiconductor imports, while Five Below's shares are down due to potential disruptions from these tariffs, with predictions of substantial cost increases affecting the retailer significantly.
Source: YAHOO